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Summary. Background: In a small group of typical hemo-
philia A (HA) patients no mutations in the F8 coding
sequence (cDNA) could be found. In the current study,
we performed a systematic screening of genetic and non-
genetic parameters associated with reduced FVIII:C levels
in a group of mostly mild HA (only one moderate)
patients with no detectable mutations in F8 cDNA. Meth-
ods: We determined FVIII and VWF activity and antigen
levels and performed VWF-FVIII binding (VWF:FVIIIB)
and VWF-collagen binding assays (VWF:CB) as well as
VWF multimer analysis. VWF was completely sequenced
to exclude mutations. The F8 locus, including the introns,
was sequenced using overlapping long-range PCRs (LR-
PCRs) combined with a next generation sequencing
(NGS) approach. Moreover, the F8 mRNA was analyzed
quantitatively and qualitatively by real-time PCR (qRT)
and overlapping reverse transcription (RT) PCRs, respec-
tively. Results: All VWF tests were normal. The LR-
PCRs demonstrated the integrity of the F8 locus. Eight
unique polymorphisms were found in the patients, with
two being recurrent. Furthermore, RT-PCRs analysis
confirmed that two of the unique variants create detect-
able new cryptic splice sites in the patients that result in
the introduction of intronic DNA sequences into the
mRNA and create premature stop codons. Conclusion: By
systematically excluding all possible causes of HA, we
could with great certainty conclude that deep intronic
mutations in F8, although rare, cause abnormal mRNA
splicing, leading to mild HA.
Keywords: factor VIII; hemophilia A; introns; mRNA;
mutations.
Introduction
HA is a monogenetic disease caused by a broad spectrum
of mutations in the factor (F) VIII gene (F8) (HAM-
STeRS; www.hadb.org.uk). Most known genetic lesions
leading to HA are within the F8 cDNA. Moreover, muta-
tions in certain domains of von Willebrand factor (VWF)
that interact with FVIII cause an HA-like phenotype
known as 2N VWD [1]. However, in about 2% of
patients with reduced FVIII:C levels presenting a typical
moderate to mild HA phenotype, no mutations could be
identified in F8 cDNA [2].
Since the discovery of the intronic regions, there has
been an increase in understanding splicing errors and
their role in pathology [3]. Traditionally, mutations affect-
ing the consensus splice-sites have been identified using a
routine intron/exon boundary screening. Once regarded
as neutral or even dispensable, intronic sequences are
now known to dictate the correct splicing of the pre-
mRNA through several elements, such as branch point
sequences, polypyrimidine tract and splice site consensus
elements [4]. Therefore, mutations or rearrangements in
the non-coding DNA have to be considered as a potential
cause of the HA phenotype in patients without mutations.
Indeed, several other studies reported the presence of cau-
sal intronic mutations. Such intronic mutations result in
an altered mRNA: either by exclusion of one or several
exons causing a severe HA phenotype [5] or through
intron inclusion leading to a mild HA phenotype [6–9].
The first is caused by mutations located within or close to
Correspondence: Osman El-Maarri, Institute of Experimental Hema-
tology and Transfusion Medicine, University of Bonn, Sigmund-
Freud-Str. 25, 53125, Bonn, Germany.
Tel.: +49 228 28716737; fax: +49 228 28714320.
E-mail: Osman.Elmaarri@ukb.uni-bonn.de
Received 26 March 2013
Manuscript handled by: L. Aledort
Final decision: F. R. Rosendaal, 23 June 2013
© 2013 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 11: 1679–1687 DOI: 10.1111/jth.12339
intron/exon boundaries, whereas the latter are found in
deep intronic regions that are not detected while applying
the routine mutation screening methods [6,8].
The aim of this study was to establish a universal system-
atic approach to investigate the molecular mechanism caus-
ing reduced FVIII:C levels in a group of mild (only one
moderate) HA patients without a mutation in F8 cDNA.
As a result we established a four-step protocol. First step:
amplification of the whole F8 locus using overlapping LR-
PCRs. Second step: NGS of LR-PCR fragments and iden-
tification of patient’s unique variants. Third step: qualita-
tive RT-PCR to detect abnormal splicing. Fourth step:
verifying the reduction of F8 mRNA at a given exon-exon
junction flanking the intron comprising the unique variant
by qRT-PCR. Using this protocol the causative intronic
mutation was identified in two patients.
Materials and methods
Samples
A total of 96 non-hemophilic males and nine HA patients
with no apparent genomic mutations in F8 cDNA are
included in this study; in addition, a further 96 healthy
males and 96 healthy females were used for screening of
the rare SNPs. Patients included in this study were previ-
ously tested for intron 1 and 22 inversions and the
recently reported intron 1 (Int1R) rearrangement [10–12].
The study was approved by the ethics committee of the
University of Bonn (approval number 183/07).
DNA isolation and mutation analysis
Genomic DNA was extracted from peripheral blood col-
lected from HA patients and healthy controls. Mutation
analysis was performed for all coding exons of F8, VWF,
LMAN1 and MCFD2. For duplication detection, MLPA
was carried out using the F8-P178 kit (MRC-Holland,
Amsterdam, the Netherlands).
F8 mRNA analysis
RNA isolation from peripheral blood and amplification
of F8 mRNA were carried out as described earlier [2].
For qRT-PCRs, a TaqMan-based assay was performed
using the AgPath-ID Kit (Life Technologies, Darmstadt,
Germany) according to the manufacturer’s instructions.
PBGD (NM_000190) and the gene expression assay
Hs00240767_m1 (Life Technologies) were used as internal
controls to normalize F8 mRNA expression (Table S1).
The allelic analysis of mRNA was carried out as
described earlier [13].
Next generation sequencing (NGS)
The complete F8 locus was amplified in 28 overlapping
PCR regions as described previously [10]. NGS was
performed on an Illumina Genome Analyzer II using
standard protocols (Illumina Inc., San Diego, CA, USA)
(Fig. 1). Briefly, for each patient the LR-PCR fragments
were equimolarly mixed and processed after fragmenta-
tion according to Illumina’s Paired-End Sequencing
library kits. Prior to that, each patient’s library was
tagged with a unique barcode. The Paired-End adapter-
ligated fragments of the pooled libraries (200 bp  50 bp)
were attached to the flow cell and amplified by bridge
amplification via PCR. The generated clusters were
sequenced and reads were aligned onto the reference
assembly NG_011403.1, allowing at most 4 mismatches/
36 bases using Geneious software (Biomatters Ltd, Auck-
land, New Zealand). The coverage varied between 72 and
692-fold. A minimum of 94.6% of the F8 locus was cov-
ered after NGS. After analysis a list of variants was gen-
erated and the significance of base calling was determined
by sorting out false-positive calls by verification of five
variants with a frequency call above 50%. A threshold of
90% call was found to be the false-positive border and a
minimum coverage of three reads was the cut-off corre-
sponding to a real variation.
Sample preparation Pre-Processing and
sequencing Bioinformatic analysis
RAW data
pre-processing
(excluding low quality reads)
Read mapping and
variant calling
(tolerate 4 mismatches/36bp)
Calling of true variants
(>90% calls, coverage >3 reads)
Excluding known
variants
(presence in dbSNP and
384 control alleles)
LR-PCRs
(28 overlapping fragments
covering the whole F8 locus)
Size-based analysis
(exclusion of duplications,
deletions, breakpoints)
Library
preparation
(Illumina Paired-End kit)
Equimolar mixture of
LR-PCRs
Patient’s specific
barcoding
Applying to Flow-
chart and bridge
amplification
NGS
(Illumina GAII)
Fig. 1. Flowchart of the NGS approach.
© 2013 International Society on Thrombosis and Haemostasis
1680 B. Pezeshkpoor et al
Splice site prediction analysis
Wild-type (wt) and mutant sequences were submitted for
splice site prediction to the Berkeley Drosophila Genome
Project (BDGP) (http://fruitfly.org/seqtools/splice.html),
NetGene2 server (http://www.dtu.dk/services/NetGene2/)
and Human Splicing Finder server (http://www.umd.be/
HSF/).
X-chromosome inactivation (XIR) and likelihood of
carriership
The XIR test was performed using the HUMARA assay
as described by Allen et al. [14]. The likelihood of being a
carrier was determined using FVIII:C values after correc-
tion for the errors/deviations introduced by age and
blood group. The transformed value (TFVIII:C) was calcu-
lated according to the formula TFVIII:C = ln(FVIII:C)-
age2 9 0.00011-bg 9 0.18017–3.61700 as described by
Oldenburg et al. [15], where bg = 0 if the subject has
blood group O or A2 and bg = 1 if A1, B or AB. The T
values were used to extrapolate the likelihood of being a
carrier or non-carrier.
Results
The clinical characteristics of typical HA were recon-
firmed in all patients (Table 1). Mutations in LMAN1,
MCFD2 and VWF were excluded (Table S2). Functional
defects of VWF protein were excluded by performing
VWF:CB, VWF:FVIIIB and multimer analysis (Table 1;
Figure S1). MLPA analysis revealed no duplications/dele-
tions in F8. Finally, translocation of F8 was excluded via
FISH analysis using a F8-specific probe (covering exons
2-26; BAC number IMGSB737DO62145D from ImaG-
enes, Berlin, Germany) in three patients (50P, 79P and
88P) (data not shown).
Identification of unique deep intronic variations in HA
patients
Forty-four intronic variations were found to fulfill the
detection threshold; 36 of them were reported in the dbSNP
database (http://www.ncbi.nlm.nih.gov/SNP/) and/or were
present in our initial cohort of 96 healthy male controls (96
alleles) (Table S3B). The remaining eight unique intronic
variations (Table S3C) were absent in an additionally
screened 288 alleles (96 male and 96 female controls)
(data not shown). Interestingly, two of the unique vari-
ants were recurrent in the analyzed patients; SNP2
(c.2113+11641insG) was present in 3P and 15P, and SNP3
(c.5586+194C>T) was present in 19P, 77P and 88P.
All eight unique variations were predicted to create
new donor and/or acceptor splice sites (dss/ass) by at
least one of the prediction softwares, except for SNP1
(c.2113+8034C>G) and SNP8 (c.6429+28519A>G). For
two SNPs [SNP5 (c.5998+941C>T, 83P) and SNP6
(c.6273+2864A>C, 79P)], the generation of new ass and
dss were predicted in intron 18 and intron 21, respec-
tively. However, the predicted strength of the new splice
site, according HSF, was lower than that of the wt site
(Table 2). For all other SNPs, the new ass and dss scores
were higher than the wt sequence. The inconsistency
between different algorithms in predicting the effect of
specific variations on splicing necessitates the verification
by experimental approaches.
RT-PCR analysis reveals aberrant splicing for two intronic
variations
In two patients (79P and 83P), aberrant mRNA tran-
scripts were observed in region C2 (exons 17-21) (Fig. 2
and S4). Sequencing of these products revealed the inclu-
sion of intronic sequences of intron 18 (105 bp and
126 bp insertion for 79P and 83P, respectively). Analysis
of the flanking sequences of these insertions at the DNA
level revealed the presence of the two unique intronic
variations identified by NGS (c.5998+530C>T and
c.5998+941G>A for 79P and 83P, respectively). The new
dss for the intronic mutation in 79P was highly predicted
by two of the prediction algorithms. However, for 83P,
the intronic variant appears to create a false splice donor
site in intron 18 of F8; AG>AA at +950 bases from exon
18. None of the splice site prediction programs predicted
this newly created site. Our sequencing results showed
that this transition activates another splice site +10 bp
downstream of the mutation.
Quantitative mRNA analysis reveals the reduction of wt F8
mRNA across exons flanking intronic mutations
As we could not find aberrant mRNA splicing in all
patients with unique intronic variations, we performed
real-time PCR analysis to measure the amount of F8
mRNA at exon boundaries where an alternative splicing
was suspected. The assay was designed for a control region
(exon 1-2 of F8) located upstream of all unique SNPs and a
test region for exon boundaries flanking an intronic varia-
tion. The ratio of F8 mRNA expression at the control
region to that at the tested region was calculated and com-
pared between the patients and healthy controls. A reduced
ratio in comparison to the controls indicates the presence
of alternative splicing at the investigated region. To vali-
date this approach, the two intronic mutations that were
proven to result in abnormal spliced products were used
(79P and 83P, Fig. 2D). For both variations, a significant
reduction in the amount of F8 mRNA in the test region
was observed (Mann-Whitney test, P = 0.0005 for
c.5998+530C>T and P = 0.0004 for c.5998+941G>A)
(Fig. 2D). This result is in accordance with the presence of
the wild-type mRNA in both patients as a faint band in the
RT-PCRs (Fig. 2C: red arrows).
© 2013 International Society on Thrombosis and Haemostasis
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Moreover, a reduction of F8 mRNA expression
(Mann–Whitney test, P = 0.019) for patient 77P was
observed in the region spanning the exons flanking SNP3
(c.5586+194C>T; also present in 19P and 88P, Figure
S5A). These data suggest the presence of an aberrant
mRNA in this patient as well. However, we could not
detect this using our nested RT-PCR approach. Probably,
this alternative splicing involves larger regions beyond the
current amplification limits of the RT-PCR approach.
For SNP2 (c.2113+11641insG in intron 13) present in
15P (and 3P), no difference in the amount of F8 mRNA
was observed when analyzing the exon 13-14 junction.
This result suggests that if this SNP is causal then
through a still elusive mechanism.
Association study of non-unique SNPs with FVIII:C, FVIII:Ag
and F8 expression
Furthermore, the effect of extra- [16] and intra-genetic
polymorphisms (detected after NGS) on reducing FVIII:
C was analyzed. Only one SNP showed borderline signifi-
cance (rs1800292 [c.3864A>C, P = 0.0627]). Moreover,
the effect of all 36 non-unique polymorphisms on F8
mRNA expression, FVIII:Ag and FVIII:C was analyzed
by performing association studies (Table S3 and Figure
S2). A significant association was found between F8
mRNA expression and rs28857481 and rs6643622
(P = 0.0326 and P = 0.0071, respectively). However, no
significant association with either FVIII:Ag nor FVIII:C
was found for these two SNPs. Among all SNPs, only
one (rs34552198, c.2114-7226_2114-7225insTA) was sig-
nificantly associated with FVIII:C (P = 0.0490), while two
showed borderline significance (rs78327897 (c.6430-
3402G>A), P = 0.0611 and rs1050705 (c*1672G>A),
P = 0.0535).
All four SNPs that showed significant or borderline sig-
nificant association with FVIII:C, were used to construct
haplotypes. In total, six haplotypes were found (Figure
S3). When stratified for the ABO polymorphism, the AA
and AG genotypes showed significant differences in
FVIII:C levels among different haplotypes (P = 0.0048).
The H4 and H5 haplotypes showed significant association
with reduced FVIII:C levels in comparison to H1, H2
and H3 haplotypes. However, all studied patients have
haplotypes associated with higher FVIII:C (3P and 15P
have haplotype H3, while the rest of the patients have
haplotype H1). This excludes the effect of common poly-
morphisms in F8 on reducing FVIII:C in the studied
patients.
For two available pedigrees index patients and potential
carriers share the same F8 allele
Family 1 The index patient shares the same allele with
five potential carriers (I-2, II-4, II-5, III-1 and III-6), only
one of whom shows significant reduction in FVIII:CT
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Fig. 2. Identification and characterization of intronic mutations for 79P and 83P. (A) Screenshot of NGS data. (B) Verification of the mutation
by Sanger sequencing (upper panel) and schematic presentation of relative position of the intronic mutations (lower panel). (C) The inserted
sequences caused by the mutations (upper panel) with RT-PCR pictures (lower panel). The red arrows indicate the faint wt mRNA band. (D)
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(III-6: 35%) (Figure S6A). For all potential carriers, the
XIR pattern was determined to explain the reason for dif-
ferences in FVIII:C levels despite carrying the allele of
the index patient. The HUMARA assay in potential carri-
ers with normal FVIII:C levels (I-2, II-4, II-5 and III-1)
showed inactivation of the index patient’s allele in 82%,
100%, 95% and 69% of the cells, respectively, explaining
their relative normal FVIII:C values. Interestingly, for
III-6, about 50% of cells were expressing the patient’s
allele, explaining the reduction in FVIII:C. Based on an
informative marker in exon 14 of F8, allelic analysis was
performed for III-1 (daughter of the index patient). Using
this assay we observed that only the non-index patient’s
allele was detected on RNA level. This result supports the
normal FVIII:C in accordance with the XIR pattern (Fig-
ure S7).
Family 2 This family includes two affected members
and three obligate carriers (Figure S6B). The index
patient (84P) has a mild phenotype with FVIII:C of 5.3%
and FVIII:Ag of 7.3%, while the other affected member
(50P) has a moderate phenotype with FVIII:C and FVIII:
Ag of 2.6% and 4%, respectively. Based on haplotype
analysis all patients and obligate carriers share the same
F8 allele. Moreover, all potential carriers show a reduc-
tion in FVIII:C in accordance with their XIR pattern.
Discussion
In a small group of clinically defined non-severe HA
patients, even after applying various mutation detection
techniques, no mutations could be detected in F8 cDNA
[2,9,17]. A number of mutations are thus being missed, as
some of these will involve sequence variations in intronic
regions that are not being assessed by routine diagnosis.
The mRNA analysis performed in this study combined
with NGS is a convenient complementary method to
prove the disease association of intronic mutations.
It is becoming more evident that deep intronic sequence
variations affect the splicing process. Deep intronic
sequence ‘exonisation’ has been reported for several
genes, such as CFTR [18], BRCA2 [19] and HRPT [20].
Also for the above genes, the importance of screening for
splicing variations has been underlined in F8. Castaman
et al. presented three different intronic variations
(c.2113+1152delA, c.5587-93C>T and c.5999-277G>A)
resulting in generation of new splice sites and premature
stop codons [6]. A single transition within intron 10
(c.1537+325A>G) was reported by Inaba et al. as a causal
mutation in a patient with mild HA [8]. Such intronic
mutations activate a cryptic donor or acceptor splice site.
Splicing between this novel splice site and a pre-existing
splice site leads to the inclusion of a cryptic exon or sim-
ply to alternative splicing.
Our mRNA analysis includes two approaches: qualita-
tive RT-PCRs to detect aberrant splicing and qRT-PCR
to determine the relative amount of F8 mRNA expression
at an exon-exon junction flanking an intronic variation. It
should be taken into consideration that as the cDNA
used in this study is synthesized from RNA obtained
from blood, which is not a known production site of
FVIII protein, possible tissue-specific splicing cannot be
neglected [21]. Therefore there is no assurance that the
effect of the variations found here will be the same in
FVIII expressing/secreting cells. Nevertheless, the impor-
tance of screening for splicing variations has been under-
lined in HA [2,5,6,13] and our work highlights the
importance of implementation of F8 mRNA analysis in
clinical practice.
Using our combined NGS and mRNA analysis proto-
col, we could determine the exact molecular defect leading
to mild HA in two patients (83P and 79P). In both cases,
intronic variations created new cryptic sites that led to
the insertion of intronic sequences in F8 mRNA between
exon 18 and 19. Both insertions introduce premature stop
codons in F8 mRNA that produce dysfunctional FVIII
protein. These truncated proteins contribute to the
slightly higher ratio of FVIII:Ag to FVIII:C levels in both
patients. Moreover, the mild phenotype is well explained
by the presence of a relatively low amount of normally
spliced F8 mRNA (demonstrated by RT-PCRs).
In a group of three patients (19P, 77P and 88P) a
recurrent unique variant in intron 16 (c.5586+194C>T)
was found. This variation did not lead to detectable
mRNA alternative splicing but to a significant reduction
of F8 mRNA expression across exons 16-17. This could
indirectly indicate that there is an abnormal mRNA
across this intron, which makes this variant highly likely
to be causative for three reasons: (i) absence in the
healthy population, (ii) it is recurrent in three unrelated
patients and (iii) the level of wt F8 mRNA is reduced
across the intron harboring this variant. However, there
is a possibility of the existence of a defect in still not iden-
tified regulatory regions or an impaired transcription of
FVIII at its main site of production, which is the liver.
In two patients (3P and 15P), a second recurrent
unique variant was detected (c.2113+11641insG). Both
qRT and qualitative mRNA analysis did not reveal
abnormalities. Although, on one hand its recurrence in
the patient population and absence in the healthy popula-
tion is suggestive of its causality, on the other hand the
absence of a detectable effect on F8 mRNA is suggestive
of a benign effect. Therefore, the causality of this varia-
tion could not be proven. The link between the variant
and the mutation mechanism could be more complex.
In the two remaining patients (50P, 84P), we could not
detect any DNA change or rearrangement across the F8
locus including the introns. However, haplotype analysis
revealed that all affected patients and potential carriers
share the same F8 allele. This result is suggestive of a
defect in F8. However, the nature of this defect is still
elusive.
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Taken together, the study presented here highlights the
necessity of looking beyond the coding, intron/exon
boundary and promoter regions, when attempting to
establish the molecular cause of a disease in the absence
of exonic mutations. We show that LR-PCRs and NGS
are likely to be useful in a diagnostic setting to clarify the
genetic basis of patients in whom no mutation through
conventional Sanger sequencing is detectable. We show
that deep intronic mutations in F8, although rare, can
cause abnormal splicing that leads to HA. We present a
comprehensive four-step protocol to investigate the cau-
sality of such intronic mutations. Our approach is univer-
sal and could be applied to any monogenic disease.
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